All In Biotech

NDA 022310 · Astrazeneca

Casodex

Bicalutamide · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Dec 19, 2008 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Dec 19, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

220

64 Phase 3, 21 recruiting

FAERS reports

15,314

12,703 serious, 2,753 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 19, 2008 Original approval · Type 6 - New Indication (no longer used) · priority review ReviewLabelLetter
1 products under this application
  • CASODEX · BICALUTAMIDE 50MG · TABLET, ORAL · Prescription · TE TBD

Clinical trials

Interventional ClinicalTrials.gov studies with "Bicalutamide" as an intervention, any sponsor and status, largest first.

All 220 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,344
  • death1,010
  • prostatic specific antigen increased951
  • asthenia819
  • hot flush804
  • prostate cancer757
  • malignant neoplasm progression725
  • drug ineffective613
  • dizziness590
  • nausea569
  • dyspnoea553
  • diarrhoea537

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004224
2005268
2006264
2007235
2008483
2009606
2010505
2011469
2012433
2013560
2014651
2015884
20161,115
20171,170
20181,305
20191,011
2020870
2021890
2022944
2023693
2024631
2025735
2026368

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Casodex (Bicalutamide)

2024 spending

$237K

Beneficiaries

17

50 claims

Per beneficiary

$13,961

$99.64 per unit

View as table
YearSpending
2020$811,316
2021$650,583
2022$420,767
2023$381,414
2024$237,333

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 250 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.